Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant

doi:https://doi.org/10.1016/j.chom.2022.10.003

Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant

Department of Biomolecular Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

The SARS-CoV-2 Omicron BA.2.75 variant emerged in May 2022. BA.2.75 is a BA.2 descendant but is phylogenetically distinct from BA.5, the currently predominant BA.2 descendant. Here, we show that BA.2.75 has a greater effective reproduction number and different immunogenicity profile than BA.5. We determined the sensitivity of BA.2.75 to vaccinee and convalescent sera as well as a panel of clinically available antiviral drugs and antibodies. Antiviral drugs largely retained potency, but antibody sensitivity varied depending on several key BA.2.75-specific substitutions. The BA.2.75 spike exhibited a profoundly higher affinity for its human receptor, ACE2. Additionally, the fusogenicity, growth efficiency in human alveolar epithelial cells, and intrinsic pathogenicity in hamsters of BA.2.75 were greater than those of BA.2. Our multilevel investigations suggest that BA.2.75 acquired virological properties independent of BA.5, and the potential risk of BA.2.75 to global health is greater than that of BA.5.

Original language	English
Pages (from-to)	1540-1555.e15
Number of pages	16
Journal	Cell Host and Microbe
Volume	30
Issue number	11
Early online date	18 Oct 2022
DOIs	https://doi.org/10.1016/j.chom.2022.10.003
State	Published - 9 Nov 2022

All Science Journal Classification (ASJC) codes

Parasitology
Microbiology
Virology

Access to Document

https://doi.org/10.1016/j.chom.2022.10.003License: CC BY

Cite this

@article{4e5c34360f924ac88cbacd0e8956dc26,

title = "Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant",

abstract = "The SARS-CoV-2 Omicron BA.2.75 variant emerged in May 2022. BA.2.75 is a BA.2 descendant but is phylogenetically distinct from BA.5, the currently predominant BA.2 descendant. Here, we show that BA.2.75 has a greater effective reproduction number and different immunogenicity profile than BA.5. We determined the sensitivity of BA.2.75 to vaccinee and convalescent sera as well as a panel of clinically available antiviral drugs and antibodies. Antiviral drugs largely retained potency, but antibody sensitivity varied depending on several key BA.2.75-specific substitutions. The BA.2.75 spike exhibited a profoundly higher affinity for its human receptor, ACE2. Additionally, the fusogenicity, growth efficiency in human alveolar epithelial cells, and intrinsic pathogenicity in hamsters of BA.2.75 were greater than those of BA.2. Our multilevel investigations suggest that BA.2.75 acquired virological properties independent of BA.5, and the potential risk of BA.2.75 to global health is greater than that of BA.5.",

author = "Akatsuki Saito and Tomokazu Tamura and Jiri Zahradnik and Sayaka Deguchi and Koshiro Tabata and Yuki Anraku and Izumi Kimura and Jumpei Ito and Daichi Yamasoba and Hesham Nasser and Mako Toyoda and Kayoko Nagata and Keiya Uriu and Yusuke Kosugi and Shigeru Fujita and Maya Shofa and {Monira Begum}, {M. S.T.} and Ryo Shimizu and Yoshitaka Oda and Gideon Schreiber",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s)",

year = "2022",

month = nov,

day = "9",

doi = "https://doi.org/10.1016/j.chom.2022.10.003",

language = "الإنجليزيّة",

volume = "30",

pages = "1540--1555.e15",

journal = "Cell Host and Microbe",

issn = "1931-3128",

publisher = "Cell Press",

number = "11",

}

TY - JOUR

T1 - Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant

AU - Saito, Akatsuki

AU - Tamura, Tomokazu

AU - Zahradnik, Jiri

AU - Deguchi, Sayaka

AU - Tabata, Koshiro

AU - Anraku, Yuki

AU - Kimura, Izumi

AU - Ito, Jumpei

AU - Yamasoba, Daichi

AU - Nasser, Hesham

AU - Toyoda, Mako

AU - Nagata, Kayoko

AU - Uriu, Keiya

AU - Kosugi, Yusuke

AU - Fujita, Shigeru

AU - Shofa, Maya

AU - Monira Begum, M. S.T.

AU - Shimizu, Ryo

AU - Oda, Yoshitaka

AU - Schreiber, Gideon

PY - 2022/11/9

Y1 - 2022/11/9

N2 - The SARS-CoV-2 Omicron BA.2.75 variant emerged in May 2022. BA.2.75 is a BA.2 descendant but is phylogenetically distinct from BA.5, the currently predominant BA.2 descendant. Here, we show that BA.2.75 has a greater effective reproduction number and different immunogenicity profile than BA.5. We determined the sensitivity of BA.2.75 to vaccinee and convalescent sera as well as a panel of clinically available antiviral drugs and antibodies. Antiviral drugs largely retained potency, but antibody sensitivity varied depending on several key BA.2.75-specific substitutions. The BA.2.75 spike exhibited a profoundly higher affinity for its human receptor, ACE2. Additionally, the fusogenicity, growth efficiency in human alveolar epithelial cells, and intrinsic pathogenicity in hamsters of BA.2.75 were greater than those of BA.2. Our multilevel investigations suggest that BA.2.75 acquired virological properties independent of BA.5, and the potential risk of BA.2.75 to global health is greater than that of BA.5.

AB - The SARS-CoV-2 Omicron BA.2.75 variant emerged in May 2022. BA.2.75 is a BA.2 descendant but is phylogenetically distinct from BA.5, the currently predominant BA.2 descendant. Here, we show that BA.2.75 has a greater effective reproduction number and different immunogenicity profile than BA.5. We determined the sensitivity of BA.2.75 to vaccinee and convalescent sera as well as a panel of clinically available antiviral drugs and antibodies. Antiviral drugs largely retained potency, but antibody sensitivity varied depending on several key BA.2.75-specific substitutions. The BA.2.75 spike exhibited a profoundly higher affinity for its human receptor, ACE2. Additionally, the fusogenicity, growth efficiency in human alveolar epithelial cells, and intrinsic pathogenicity in hamsters of BA.2.75 were greater than those of BA.2. Our multilevel investigations suggest that BA.2.75 acquired virological properties independent of BA.5, and the potential risk of BA.2.75 to global health is greater than that of BA.5.

UR - http://www.scopus.com/inward/record.url?scp=85140772999&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.chom.2022.10.003

DO - https://doi.org/10.1016/j.chom.2022.10.003

M3 - مقالة

C2 - 36272413

SN - 1931-3128

VL - 30

SP - 1540-1555.e15

JO - Cell Host and Microbe

JF - Cell Host and Microbe

IS - 11

ER -

Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this